Literature DB >> 16936712

The cognitive effects of electroconvulsive therapy in community settings.

Harold A Sackeim1, Joan Prudic, Rice Fuller, John Keilp, Philip W Lavori, Mark Olfson.   

Abstract

Despite ongoing controversy, there has never been a large-scale, prospective study of the cognitive effects of electroconvulsive therapy (ECT). We conducted a prospective, naturalistic, longitudinal study of clinical and cognitive outcomes in patients with major depression treated at seven facilities in the New York City metropolitan area. Of 751 patients referred for ECT with a provisional diagnosis of a depressive disorder, 347 patients were eligible and participated in at least one post-ECT outcome evaluation. The primary outcome measures, Modified Mini-Mental State exam scores, delayed recall scores from the Buschke Selective Reminding Test, and retrograde amnesia scores from the Columbia University Autobiographical Memory Interview-SF (AMI-SF), were evaluated shortly following the ECT course and 6 months later. A substantial number of secondary cognitive measures were also administered. The seven sites differed significantly in cognitive outcomes both immediately and 6 months following ECT, even when controlling for patient characteristics. Electrical waveform and electrode placement had marked cognitive effects. Sine wave stimulation resulted in pronounced slowing of reaction time, both immediately and 6 months following ECT. Bilateral (BL) ECT resulted in more severe and persisting retrograde amnesia than right unilateral ECT. Advancing age, lower premorbid intellectual function, and female gender were associated with greater cognitive deficits. Thus, adverse cognitive effects were detected 6 months following the acute treatment course. Cognitive outcomes varied across treatment facilities and differences in ECT technique largely accounted for these differences. Sine wave stimulation and BL electrode placement resulted in more severe and persistent deficits.

Entities:  

Mesh:

Year:  2006        PMID: 16936712     DOI: 10.1038/sj.npp.1301180

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  84 in total

Review 1.  Somatic treatments for mood disorders.

Authors:  Moacyr A Rosa; Sarah H Lisanby
Journal:  Neuropsychopharmacology       Date:  2011-10-05       Impact factor: 7.853

2.  Stuck in a rut: rethinking depression and its treatment.

Authors:  Paul E Holtzheimer; Helen S Mayberg
Journal:  Trends Neurosci       Date:  2010-11-08       Impact factor: 13.837

Review 3.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

4.  A Review of Brain Stimulation Treatments for Late-Life Depression.

Authors:  Daniel M Blumberger; Jonathan H Hsu; Zafiris J Daskalakis
Journal:  Curr Treat Options Psychiatry       Date:  2015-09-28

Review 5.  Neurobiological mechanisms in major depressive disorder.

Authors:  Marije aan het Rot; Sanjay J Mathew; Dennis S Charney
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

Review 6.  Neuromodulation for treatment-refractory major depressive disorder.

Authors:  Nir Lipsman; Tejas Sankar; Jonathan Downar; Sidney H Kennedy; Andres M Lozano; Peter Giacobbe
Journal:  CMAJ       Date:  2013-07-29       Impact factor: 8.262

7.  Short- and Long-term Cognitive Outcomes in Patients With Major Depression Treated With Electroconvulsive Therapy.

Authors:  Megha M Vasavada; Amber M Leaver; Stephanie Njau; Shantanu H Joshi; Linda Ercoli; Gerhard Hellemann; Katherine L Narr; Randall Espinoza
Journal:  J ECT       Date:  2017-12       Impact factor: 3.635

8.  A two-site, open-label, non-randomized trial comparing Focal Electrically-Administered Seizure Therapy (FEAST) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT).

Authors:  Gregory L Sahlem; William V McCall; E Baron Short; Peter B Rosenquist; James B Fox; Nagy A Youssef; Andrew J Manett; Suzanne E Kerns; Morgan M Dancy; Laryssa McCloud; Mark S George; Harold A Sackeim
Journal:  Brain Stimul       Date:  2020-07-29       Impact factor: 8.955

Review 9.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

10.  A functional MRI marker may predict the outcome of electroconvulsive therapy in severe and treatment-resistant depression.

Authors:  J A van Waarde; H S Scholte; L J B van Oudheusden; B Verwey; D Denys; G A van Wingen
Journal:  Mol Psychiatry       Date:  2014-08-05       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.